“Respiratory Syncytial Virus Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Respiratory Syncytial Virus Market.
The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Respiratory Syncytial Virus Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Respiratory Syncytial Virus treatment therapies with a considerable amount of success over the years.
-
Respiratory Syncytial Virus companies working in the treatment market are GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others, are developing therapies for the Respiratory Syncytial Virus treatment
-
Emerging Respiratory Syncytial Virus therapies in the different phases of clinical trials are- Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others are expected to have a significant impact on the Respiratory Syncytial Virus market in the coming years.
-
In June 2025, MSD’s Enflonsia (clesrovimab) has been approved by the FDA for preventing respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants entering or born during their first RSV season. Enflonsia is a long-acting monoclonal antibody that offers protection for an entire five-month RSV season with a single 105mg dose, regardless of the infant's weight. The approval is backed by results from the Phase IIb/III CLEVER trial (NCT04767373), which showed that a single dose of Enflonsia reduced RSV-related medically attended lower respiratory infections by 60.5% and hospitalizations by 84.3% over five months, compared to placebo.
-
In April 2025, GSK plc (LSE/NYSE: GSK) has announced that the Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of RSV vaccines, including GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted), for adults aged 50–59 who are at higher risk of severe RSV illness. This group includes individuals with underlying health conditions such as COPD, asthma, diabetes, heart disease, and those living in care facilities. This recommendation builds on ACIP’s earlier June 2024 vote endorsing RSV vaccination for adults aged 60–74 at increased risk, and all adults aged 75 and above. AREXVY is approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 and older, and now also in those aged 50–59 at heightened risk for RSV-related LRTD.
-
In February 2025, Inhalon Biopharma, a US-based company, is preparing to initiate a clinical trial of its at-home nebulized therapy for respiratory syncytial virus (RSV) through the FluCamp program. The investigational treatment, IN-002, will be evaluated in a human challenge study in partnership with the German contract research organization (CRO) hVIVO. The CRO has confirmed plans to utilize FluCamp to recruit participants for the trial, which is scheduled to begin in 2026. FluCamp enrolls healthy volunteers to take part in clinical studies focused on developing treatments for illnesses like RSV.
-
In January 2025, Shionogi’s oral antiviral candidate for respiratory syncytial virus (RSV), S-337395, has achieved its primary endpoint in a Phase II clinical trial, with some participants experiencing an 88.94% reduction in viral load. The Japanese pharmaceutical company reported positive outcomes from this Phase II human challenge study, in which volunteers were deliberately infected with RSV to assess the treatment’s effectiveness in reducing the virus’s impact.
-
In December 2024, Blue Lake Biotechnology, a US-based clinical-stage company specializing in intranasal vaccines, reported that its pediatric nasal vaccine for respiratory syncytial virus (RSV), BLB201, demonstrated safety and efficacy in pediatric patients during a Phase I/IIa clinical trial.
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a common respiratory virus that primarily affects young children and older adults. It can cause mild, cold-like symptoms in healthy individuals, but it can lead to severe respiratory infections, particularly in infants, older adults, and individuals with weakened immune systems.
Get a Free Sample PDF Report to know more about Respiratory Syncytial Virus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight
Emerging Respiratory Syncytial Virus Drugs Under Different Phases of Clinical Development Include:
-
Nirsevimab (MEDI-8897): MedImmune
-
Sisunatovir: ReViral
-
MVA-BN-RSV Vaccine: Bavarian Nordic
-
RSVpreF (PF-06928316): Pfizer
-
VAC 18193 (Ad26.RSV.preF): Janssen
-
mRNA-1345: ModernaTX, Inc
-
GSK3844766A: GlaxoSmithKline
-
RSVPreF3: GlaxoSmithKline
-
STR-V003/Placebo: Starna Therapeutics
-
TNM001: Zhuhai Trinomab Pharma
-
Sisunatovir: Pfizer
-
RSVt Vaccine: Sanofi
-
Deuremidevir Hydrobromide for Suspension: Vigonvita Life Sciences
-
Nirsevimab: AstraZeneca
-
TNM001: Zhuhai Trinomab Pharma
-
Clesrovimab: Merck Sharp & Dohme LLC
-
EDP-938: Enanta Pharmaceuticals
Route of Administration
Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical.
-
Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Respiratory Syncytial Virus Pipeline Therapeutics Assessment
-
Respiratory Syncytial Virus Assessment by Product Type
-
Respiratory Syncytial Virus By Stage and Product Type
-
Respiratory Syncytial Virus Assessment by Route of Administration
-
Respiratory Syncytial Virus By Stage and Route of Administration
-
Respiratory Syncytial Virus Assessment by Molecule Type
-
Respiratory Syncytial Virus by Stage and Molecule Type
DelveInsight's Respiratory Syncytial Virus Report covers around 55+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Respiratory Syncytial Virus product details are provided in the report. Download the Respiratory Syncytial Virus pipeline report to learn more about the emerging Respiratory Syncytial Virus therapies
Respiratory Syncytial Virus Pipeline Analysis:
The Respiratory Syncytial Virus pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
-
Respiratory Syncytial Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Respiratory Syncytial Virus drugs and therapies
Respiratory Syncytial Virus Pipeline Market Drivers
-
Rising government funding for treatment and proactive government initiatives generates profitable opportunities, the growing disease rate, advent of Targeted Therapies are some of the important factors that are fueling the Respiratory Syncytial Virus Market.
Respiratory Syncytial Virus Pipeline Market Barriers
-
However, lack of adequate diagnostic facilities for RSV, limited awareness among parents and other factors are creating obstacles in the Respiratory Syncytial Virus Market growth.
Scope of Respiratory Syncytial Virus Pipeline Drug Insight
-
Coverage: Global
-
Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others
-
Key Respiratory Syncytial Virus Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others
-
Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies
-
Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers
Request for Sample PDF Report for Respiratory Syncytial Virus Pipeline Assessment and clinical trials
Table of Contents
| 1 | Respiratory Syncytial Virus Report Introduction |
| 2 | Respiratory Syncytial Virus Executive Summary |
| 3 | Respiratory Syncytial Virus Overview |
| 4 | Respiratory Syncytial Virus- Analytical Perspective In-depth Commercial Assessment |
| 5 | Respiratory Syncytial Virus Pipeline Therapeutics |
| 6 | Respiratory Syncytial Virus Late Stage Products (Phase II/III) |
| 7 | Respiratory Syncytial Virus Mid Stage Products (Phase II) |
| 8 | Respiratory Syncytial Virus Early Stage Products (Phase I) |
| 9 | Respiratory Syncytial Virus Preclinical Stage Products |
| 10 | Respiratory Syncytial Virus Therapeutics Assessment |
| 11 | Respiratory Syncytial Virus Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Respiratory Syncytial Virus Key Companies |
| 14 | Respiratory Syncytial Virus Key Products |
| 15 | Respiratory Syncytial Virus Unmet Needs |
| 16 | Respiratory Syncytial Virus Market Drivers and Barriers |
| 17 | Respiratory Syncytial Virus Future Perspectives and Conclusion |
| 18 | Respiratory Syncytial Virus Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
